Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11 - 30; http://dx.doi.org/10.3322/caac.21166; PMID: 23335087
   PubMed Web of Science ®Google Scholar
• Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 2013; 14:236 - 43; http://dx.doi.org/10.1016/S1470-2045(12)70567-3; PMID: 23333117
   PubMed Web of Science ®Google Scholar
• Banerjee S, Gore M. The future of targeted therapies in ovarian cancer. Oncologist 2009; 14:706 - 16; http://dx.doi.org/10.1634/theoncologist.2009-0013; PMID: 19592450
   PubMed Web of Science ®Google Scholar
• Landen CN Jr., Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26:995 - 1005; http://dx.doi.org/10.1200/JCO.2006.07.9970; PMID: 18195328
   PubMed Web of Science ®Google Scholar
• Lee JW, Shahzad MMK, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009; 15:2695 - 702; http://dx.doi.org/10.1158/1078-0432.CCR-08-2966; PMID: 19351748
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al, ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365:2484 - 96; http://dx.doi.org/10.1056/NEJMoa1103799; PMID: 22204725
   PubMed Web of Science ®Google Scholar
• Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010; 1:12 - 25; http://dx.doi.org/10.1177/1947601909356574; PMID: 21779425
   PubMedGoogle Scholar
• Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010; 13:16 - 28; http://dx.doi.org/10.1016/j.drup.2009.12.001; PMID: 20061178
   PubMed Web of Science ®Google Scholar
• Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies. Oncologist 2012; 17:1039 - 50; http://dx.doi.org/10.1634/theoncologist.2012-0068; PMID: 22773560
   PubMed Web of Science ®Google Scholar
• Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Mol Aspects Med 2011; 32:71 - 87; http://dx.doi.org/10.1016/j.mam.2011.04.001; PMID: 21540050
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A. Overcoming antiangiogenic resistance. Clin Cancer Res 2011; 17:5217 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-11-1219; PMID: 21828238
   PubMed Web of Science ®Google Scholar
• Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010; 86:12 - 9; http://dx.doi.org/10.1093/cvr/cvp332; PMID: 19812043
   PubMed Web of Science ®Google Scholar
• Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67:1757 - 68; http://dx.doi.org/10.1158/0008-5472.CAN-06-3700; PMID: 17308118
   PubMed Web of Science ®Google Scholar
• Ødegaard E, Davidson B, Engh V, Onsrud M, Staff AC. Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol 2008; 199:e1 - 8; http://dx.doi.org/10.1016/j.ajog.2008.04.004; PMID: 18533117
   PubMedGoogle Scholar
• Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, et al. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 2013; 19:170 - 82; http://dx.doi.org/10.1158/1078-0432.CCR-12-1045; PMID: 23147994
   PubMed Web of Science ®Google Scholar
• Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 2003; 9:4221 - 6; PMID: 14519649
   PubMed Web of Science ®Google Scholar
• Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, McConkey DJ. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 2004; 64:4601 - 10; http://dx.doi.org/10.1158/0008-5472.CAN-2879-2; PMID: 15231672
   PubMed Web of Science ®Google Scholar
• Taskiran C, Erdem O, Onan A, Arisoy O, Acar A, Vural C, Erdem M, Ataoglu O, Guner H. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 2006; 16:1789 - 93; http://dx.doi.org/10.1111/j.1525-1438.2006.00658.x; PMID: 17009973
   PubMed Web of Science ®Google Scholar
• Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol 2011; 32:589 - 96; http://dx.doi.org/10.1007/s13277-011-0157-6; PMID: 21350924
   PubMed Web of Science ®Google Scholar
• Banerjee S, Dhara SK, Bacanamwo M. Endoglin is a novel endothelial cell specification gene. Stem Cell Res 2012; 8:85 - 96; http://dx.doi.org/10.1016/j.scr.2011.08.006; PMID: 22099023
   PubMed Web of Science ®Google Scholar
• Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H, Seon BK. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009; 125:1446 - 53; http://dx.doi.org/10.1002/ijc.24482; PMID: 19533687
   PubMed Web of Science ®Google Scholar
• Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo GM, Dejana E, Wrana JL, Letarte M. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor β1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem 2005; 280:27800 - 8; http://dx.doi.org/10.1074/jbc.M503471200; PMID: 15923183
   PubMed Web of Science ®Google Scholar
• Lee NY, Ray B, How T, Blobe GC. Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 2008; 283:32527 - 33; http://dx.doi.org/10.1074/jbc.M803059200; PMID: 18775991
   PubMed Web of Science ®Google Scholar
• Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17:1159 - 61; PMID: 12709414
   PubMed Web of Science ®Google Scholar
• Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 2008; 11:219 - 30; http://dx.doi.org/10.1016/j.drup.2008.09.001; PMID: 18948057
   PubMed Web of Science ®Google Scholar
• Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 2009; 335:205 - 22; http://dx.doi.org/10.1007/s00441-008-0642-4; PMID: 18677515
   PubMed Web of Science ®Google Scholar
• Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008; 99:459 - 66; http://dx.doi.org/10.1111/j.1349-7006.2007.00704.x; PMID: 18167133
   PubMed Web of Science ®Google Scholar
• Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64:8249 - 55; http://dx.doi.org/10.1158/0008-5472.CAN-04-1567; PMID: 15548691
   PubMed Web of Science ®Google Scholar
• Ghosh K, Thodeti CK, Dudley AC, Mammoto A, Klagsbrun M, Ingber DE. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc Natl Acad Sci U S A 2008; 105:11305 - 10; http://dx.doi.org/10.1073/pnas.0800835105; PMID: 18685096
   PubMed Web of Science ®Google Scholar
• McLaughlin N, Annabi B, Sik Kim K, Bahary JP, Moumdjian R, Béliveau R. The response to brain tumor-derived growth factors is altered in radioresistant human brain endothelial cells. Cancer Biol Ther 2006; 5:1539 - 45; http://dx.doi.org/10.4161/cbt.5.11.3459; PMID: 17102591
   PubMed Web of Science ®Google Scholar
• Suh LH, Zhang C, Chuck RS, Stark WJ, Naylor S, Binley K, Chakravarti S, Jun AS. Cryopreservation and lentiviral-mediated genetic modification of human primary cultured corneal endothelial cells. Invest Ophthalmol Vis Sci 2007; 48:3056 - 61; http://dx.doi.org/10.1167/iovs.06-0771; PMID: 17591873
   PubMed Web of Science ®Google Scholar
• Wanisch K, Yáñez-Muñoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009; 17:1316 - 32; http://dx.doi.org/10.1038/mt.2009.122; PMID: 19491821
   PubMed Web of Science ®Google Scholar
• Goodwin AM. In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 2007; 74:172 - 83; http://dx.doi.org/10.1016/j.mvr.2007.05.006; PMID: 17631914
   PubMed Web of Science ®Google Scholar
• Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 2012; 18:4820 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-12-0098; PMID: 22767667
   PubMed Web of Science ®Google Scholar
• Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468:829 - 33; http://dx.doi.org/10.1038/nature09624; PMID: 21102433
   PubMed Web of Science ®Google Scholar
• Ribatti D. Cancer stem cells and tumor angiogenesis. Cancer Lett 2012; 321:13 - 7; http://dx.doi.org/10.1016/j.canlet.2012.02.024; PMID: 22388173
   PubMed Web of Science ®Google Scholar
• Wheeler-Jones CP, Clarkin CE, Farrar CE, Dhadda P, Chagastelles P, Nardi N, Jones PM. Endoglin (CD105) is not a specific selection marker for endothelial cells in human islets of Langerhans. Diabetologia 2013; 56:222 - 4; http://dx.doi.org/10.1007/s00125-012-2763-2; PMID: 23104640
   PubMed Web of Science ®Google Scholar
• Schellerer VS, Croner RS, Weinländer K, Hohenberger W, Stürzl M, Naschberger E. Endothelial cells of human colorectal cancer and healthy colon reveal phenotypic differences in culture. Lab Invest 2007; 87:1159 - 70; http://dx.doi.org/10.1038/labinvest.3700671; PMID: 17876298
   PubMed Web of Science ®Google Scholar
• Plendl J, Neumüller C, Vollmar A, Auerbach R, Sinowatz F. Isolation and characterization of endothelial cells from different organs of fetal pigs. Anat Embryol (Berl) 1996; 194:445 - 56; http://dx.doi.org/10.1007/BF00185992; PMID: 8905012
   PubMedGoogle Scholar
• Ray BN, Lee NY, How T, Blobe GC. ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis 2010; 31:435 - 41; http://dx.doi.org/10.1093/carcin/bgp327; PMID: 20042635
   PubMed Web of Science ®Google Scholar
• Benetti A, Berenzi A, Gambarotti M, Garrafa E, Gelati M, Dessy E, Portolani N, Piardi T, Giulini SM, Caruso A, et al. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res 2008; 68:8626 - 34; http://dx.doi.org/10.1158/0008-5472.CAN-08-1218; PMID: 18922939
   PubMed Web of Science ®Google Scholar
• Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004; 23:4018 - 28; http://dx.doi.org/10.1038/sj.emboj.7600386; PMID: 15385967
   PubMed Web of Science ®Google Scholar
• Petrocca F, Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 2011; 29:747 - 54; http://dx.doi.org/10.1200/JCO.2009.27.6287; PMID: 21079135
   PubMed Web of Science ®Google Scholar
• Andersen ND, Monahan TS, Malek JY, Jain M, Daniel S, Caron LD, Pradhan L, Ferran C, Logerfo FW. Comparison of gene silencing in human vascular cells using small interfering RNAs. J Am Coll Surg 2007; 204:399 - 408; http://dx.doi.org/10.1016/j.jamcollsurg.2006.12.029; PMID: 17324773
   PubMed Web of Science ®Google Scholar
• Liu Y, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood 2006; 107:3027 - 33; http://dx.doi.org/10.1182/blood-2005-10-4114; PMID: 16373660
   PubMed Web of Science ®Google Scholar
• Lu PY, Xie FY, Woodle MC. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol Med 2005; 11:104 - 13; http://dx.doi.org/10.1016/j.molmed.2005.01.005; PMID: 15760768
   PubMed Web of Science ®Google Scholar
• Li CHI, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells. FASEB J 2000; 14:55 - 64; PMID: 10627280
   PubMed Web of Science ®Google Scholar
• She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-β in suppression of growth of human endothelial cells. Int J Cancer 2004; 108:251 - 7; http://dx.doi.org/10.1002/ijc.11551; PMID: 14639611
   PubMed Web of Science ®Google Scholar
• Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 2009; 1792:954 - 73; http://dx.doi.org/10.1016/j.bbadis.2009.07.003; PMID: 19607914
   PubMed Web of Science ®Google Scholar
• Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-β receptor in human cancer. Cell Signal 2010; 22:1163 - 74; http://dx.doi.org/10.1016/j.cellsig.2010.01.016; PMID: 20153821
   PubMed Web of Science ®Google Scholar
• Bernabeu C, Conley BA, Vary CP. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 2007; 102:1375 - 88; http://dx.doi.org/10.1002/jcb.21594; PMID: 17975795
   PubMed Web of Science ®Google Scholar
• Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Löwik CW, ten Dijke P. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007; 120:964 - 72; http://dx.doi.org/10.1242/jcs.002949; PMID: 17311849
   PubMed Web of Science ®Google Scholar
• Lee NY, Golzio C, Gatza CE, Sharma A, Katsanis N, Blobe GC. Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis. Mol Biol Cell 2012; 23:2412 - 23; http://dx.doi.org/10.1091/mbc.E11-12-0993; PMID: 22593212
   PubMed Web of Science ®Google Scholar
• Staton CA, Reed MWR, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol 2009; 90:195 - 221; http://dx.doi.org/10.1111/j.1365-2613.2008.00633.x; PMID: 19563606
   PubMed Web of Science ®Google Scholar